MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Organon & Co

Închisă

SectorSănătate

9.56 -2.65

Rezumat

Modificarea prețului

24h

Curent

Minim

9.54

Maxim

9.84

Indicatori cheie

By Trading Economics

Venit

-22M

87M

Vânzări

-79M

1.5B

P/E

Medie Sector

3.375

39.564

Randament dividend

0.83

Marjă de profit

5.75

Angajați

10,000

EBITDA

-13M

325M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+40.85% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.83%

2.40%

Următoarele câștiguri

5 aug. 2025

Data viitoare de dividende

11 sept. 2025

Următoarea dată ex-dividende

15 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.6B

2.5B

Deschiderea anterioară

12.21

Închiderea anterioară

9.56

Sentimentul știrilor

By Acuity

26%

74%

46 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Organon & Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 iul. 2025, 22:07 UTC

Principalele dinamici ale pieței

Trade Desk Rises on S&P 500 Inclusion

14 iul. 2025, 17:06 UTC

Principalele dinamici ale pieței

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 iul. 2025, 16:47 UTC

Achiziții, Fuziuni, Preluări

NatWest to Sell Stake in Permanent TSB

14 iul. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 iul. 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 iul. 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 iul. 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 iul. 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 iul. 2025, 23:02 UTC

Câștiguri

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 iul. 2025, 23:02 UTC

Câștiguri

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 iul. 2025, 23:02 UTC

Câștiguri

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 iul. 2025, 23:01 UTC

Câștiguri

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 iul. 2025, 23:01 UTC

Câștiguri

China Vanke Expects 1H Loss to Widen >000002.SZ

14 iul. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 iul. 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 iul. 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 iul. 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 iul. 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 iul. 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 iul. 2025, 18:30 UTC

Achiziții, Fuziuni, Preluări

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 iul. 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 iul. 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 iul. 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 iul. 2025, 16:53 UTC

Acțiuni populare

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 iul. 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

14 iul. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 iul. 2025, 16:12 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Comparație

Modificare preț

Organon & Co Așteptări

Obiectiv de preț

By TipRanks

40.85% sus

Prognoză pe 12 luni

Medie 14 USD  40.85%

Maxim 18 USD

Minim 10 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOrganon & Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

2

Cumpărare

3

Păstrare

2

Vânzare

Scor tehnic

By Trading Central

8.53 / 9.18Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

46 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.